To determine the safety of performing urgent or emergent cardiac surgery within 5
days of a patient taking a direct oral anticoagulant (DOAC).
A multicenter retrospective registry study.
Thirty-three hospitals in a quality collaborative from 2017 to 2019.
Patients were included if they underwent urgent or emergent coronary artery bypass
grafting (CABG). Patients were excluded if they received any anticoagulant or antiplatelet
agent besides DOACs, heparin, or aspirin.
Patients were stratified based upon the receipt of a DOAC within 5 days of their surgery.
Patient cohorts included DOAC within 2 days, DOAC within 3-to-5 days, and no anticoagulation.
Data were unavailable on the specific DOAC agent taken prior to admission.
Measurements and Main Results
There were 7,201 patients included, with 94 on DOACs. Intraoperative blood transfusion
was required in 23.9% of patients on no anticoagulant, 26.2% on a DOAC within 3-to-5
days of surgery (odds ratio [OR] 0.98; 95% CI 0.46-2.11), and 30.3% on a DOAC within
2 days (OR 0.99; 95% CI 0.37-2.67). Five or more intraoperative blood products were
required in 4.4% on no anticoagulant, 1.7% on DOAC within 3-to-5 days (OR 0.33; 95%
CI 0.04-2.71), and 6.1% on DOAC within 2 days (OR 0.47; 95% CI 0.06-4.05). No difference
in mortality was observed among the 3 groups (2.9% v 3.3% v 3.0%; p = 0.67).
For urgent or emergent CABGs, no significant differences in minor bleeding, major
bleeding, or mortality were observed in patients taking a DOAC within 5 days of surgery.
This study was hypothesis-generating for performing urgent or emergent surgery sooner
than 5 days after holding DOACs.